Anti-Cleaved PARP antibody [4B5BD2] (ab110315)

Overview

  • Product nameAnti-Cleaved PARP antibody [4B5BD2]
    See all Cleaved PARP primary antibodies
  • Description
    Mouse monoclonal [4B5BD2] to Cleaved PARP
  • Specificityab110315 reacts with the N-terminal end formed by the cleavage adjacent to Asp214; it thus recognizes the apoptosis-specific 89 kDa catalytic domain fragment, but it does not recognize the full-length PARP-1 or the 24 kDa DNA binding domain fragment.
  • Tested applicationsSuitable for: WB, ICC/IF, In-Cell ELISA, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human Cleaved PARP (N terminal).
    Sequence:

    GVDEVAKKKSKKEK-C

  • Positive control
    • Staurosporine-treated HeLa and HL60 cells
  • General notes

    Product was previously marketed under the MitoSciences sub-brand.

     

    Alternative versions available:

    Anti-Cleaved PARP antibody (Alexa Fluor® 488) [4B5BD2] (ab170171)

    Anti-Cleaved PARP antibody (HRP) [4B5BD2] (ab198490)

Properties

Applications

Our Abpromise guarantee covers the use of ab110315 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.25 - 1 µg/ml. Predicted molecular weight: 113 kDa.
ICC/IF Use a concentration of 1 µg/ml.
In-Cell ELISA Use a concentration of 1 µg/ml.
Flow Cyt Use a concentration of 1 µg/ml.

ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

Target

  • FunctionInvolved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Mediates the poly(ADP-ribosyl)ation of APLF and CHFR. Positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. With EEF1A1 and TXK, forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFN-gamma to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production. Required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites.
  • Sequence similaritiesContains 1 BRCT domain.
    Contains 1 PARP alpha-helical domain.
    Contains 1 PARP catalytic domain.
    Contains 2 PARP-type zinc fingers.
  • Post-translational
    modifications
    Phosphorylated by PRKDC and TXK.
    Poly-ADP-ribosylated by PARP2. Poly-ADP-ribosylation mediates the recruitment of CHD1L to DNA damage sites.
    S-nitrosylated, leading to inhibit transcription regulation activity.
  • Cellular localizationNucleus. Nucleus, nucleolus. Localizes at sites of DNA damage.
  • Information by UniProt
  • Database links
  • Alternative names
    • ADP-ribosyltransferase diphtheria toxin-like 1 antibody
    • ADPRT 1 antibody
    • ADPRT antibody
    • ADPRT1 antibody
    • APOPAIN antibody
    • ARTD1 antibody
    • NAD(+) ADP-ribosyltransferase 1 antibody
    • PARP antibody
    • PARP-1 antibody
    • PARP1 antibody
    • PARP1_HUMAN antibody
    • Poly [ADP-ribose] polymerase 1 antibody
    • Poly ADP ribose polymerase 1 antibody
    • Poly[ADP-ribose] synthase 1 antibody
    • PPOL antibody
    • SCA1 antibody
    see all

Anti-Cleaved PARP antibody [4B5BD2] images

  • Lanes 1 - 2 : Antibody that recognizes full-length PARP1
    Lanes 3 - 4 : Anti-Cleaved PARP antibody [4B5BD2] (ab110315) at 1 µg/ml

    Lane 1 : untreated HeLa cells
    Lane 2 : HeLa cells treated with 1 µM Staurosporinefor 4 hours
    Lane 3 : untreated HeLa cells
    Lane 4 : HeLa cells treated with 1 µM Staurosporinefor 4 hours

    Lysates/proteins at 20 µg per lane.


    Predicted band size : 113 kDa
    Western Blot analysis using ab110315 antibody and 20 µg of untreated (CON) or 4 hours 1 µM Staurosporine-treated (STS) HeLa cells. Blots were incubated with an antibody that recognizes both the full-length PARP-1 and its 89 kDa fragment (left panel), or 1.0 µg/mL PARP-1 (cleaved) antibody (ab110315) (right panel). Appropriate HRP-conjugated secondary antibodies followed by ECL detection were used. Note that the MS777 antibody recognizes the apoptosis-specific 89 kDa fragment of PARP-1 but it does not recognize the full-length PARP-1.
  • Immunocytochemistry images of stained untreated (A) and 4 hours 1 µM Staurosporine-treated (B) Human HeLa cells. The cells were paraformaldehyde fixed (4%, 20 minutes) and Triton X-100 permeabilized (0.1%, 15 minutes). The cells were incubated with 1.0 µg/ml ab110315 for 2 hours at room temperature or over night at 4°C. 10% goat serum was used as the blocking agent for all blocking steps. The secondary antibody was Alexa Fluor® 488 goat anti-mouse IgG (H+L) (in green) used at 2.0 µg/ml for 2 hours. DAPI was used to stain the cell nuclei (in red). Heat induced antigen retrieval (0.1 M Tris-HCl, 5% urea, pH 9.5 for 5 min at 95°C) improves signal. Note that the ab110315 labels only condensed and/or fragmented nuclei of apoptotic Staurosporine-treated cells.
  • In-Cell ELISA (ICE) using ab110315 on HeLa cells treated with Staurosporine to induce apoptosis. HeLa cells were seeded overnight (50,000 cells/well), treated for 4 hours with 1 µM Staurosporine or with the drug vehicle (DMSO), fixed for Detaching Adherent Cells and analyzed.
  • Flow cytometry analysis of apoptosis using ab110315. HL-60 cells were treated with 1 µM Staurosporin for 4 hours (blue) or vehicle control (red). Control cells were also stained with an equal amount of an isotype control antibody (black).

References for Anti-Cleaved PARP antibody [4B5BD2] (ab110315)

This product has been referenced in:
  • Arosh JA  et al. Molecular and preclinical basis to inhibit PGE2 receptors EP2 and EP4 as a novel nonsteroidal therapy for endometriosis. Proc Natl Acad Sci U S A 112:9716-21 (2015). IHC-Fr ; Mouse . Read more (PubMed: 26199416) »

See 1 Publication for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (epithelial ovacar cell line)
Gel Running Conditions Reduced Denaturing (7.5%)
Loading amount 100 µg
Treatment 0-200uM Perifosine
Specification epithelial ovacar cell line
Blocking step Milk as blocking agent for 12 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C
Username

Abcam user community

Verified customer

Submitted Jul 26 2016

Application Western blot
Loading amount 75 µg
Gel Running Conditions Reduced Denaturing (10)
Sample Rat Cell lysate - other (Gonad)
Specification Gonad
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Sep 12 2013

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa)
Specification HeLa
Fixative Paraformaldehyde
Permeabilization Yes - 0.5% Triton X-100 in PBS
Username

Dr. Kirk McManus

Verified customer

Submitted Feb 20 2013

Thank you very much for your inquiry.

I am sorry to confirm, that the laboratory has tested this antibody on mouse tissue and has obtained negative results. We will try to add this information to our datasheets - I apologize that for the mome...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"